Science Corp’s PRIMA Retinal Implant Receives CE Mark for European Commercial Launch

Jul 22, 2026

Science Corporation has launched its PRIMA retinal implant in Europe after receiving CE mark approval, offering a novel treatment to restore central vision for patients with age-related macular degeneration. The wireless 2x2 mm implant, paired with specialized glasses, successfully restored reading capabilities for 84% of patients in a 38-person clinical trial. While the device is expected to cost hundreds of thousands of dollars, commercial rollouts and reimbursement discussions are underway, starting in Germany.

PRIMA retinal implant European approval

▪The CE mark authorizes the commercial availability of the PRIMA retinal implant across 30 European countries.
▪Science Corporation announced the European commercial launch of its PRIMA retinal implant after receiving a CE mark under the European Union Medical Device Regulation from DEKRA.
▪Science Corporation is working with the United States Food and Drug Administration to bring the PRIMA retinal implant to the United States market, where it has received Breakthrough Device and Humanitarian Use Device designations.

Age-related macular degeneration treatment

▪The PRIMA retinal implant is the first brain-computer interface device to receive a CE marking for form vision restoration, such as reading letters, numbers, and words.
▪Age-related macular degeneration destroys light-sensitive photoreceptor cells at the center of the retina, affecting more than five million people globally and causing progressive loss of central vision.

Science Corporation business strategy

▪Science Corporation founder Max Hodak, who co-founded Neuralink, aims to build a sustainable business restoring vision to finance long-term bio-hybrid brain sensor technologies.
▪Science Corporation acquired Pixium, the French company that developed the PRIMA technology, in 2024.

PRIMA device implant procedure

▪The PRIMA system consists of a 2 by 2 millimeter wireless subretinal photovoltaic implant paired with camera-equipped glasses that project near-infrared light to stimulate the implant.
▪Patients receive the PRIMA implant through an hour-long outpatient procedure that places the chip under the atrophic macula at the back of the eye.

Vision restoration patient outcomes

▪Clinical trial results showed that 80% of patients achieved significant prosthetic visual acuity improvements of at least logMAR 0.2 at 12 months without a decline in existing natural vision.
▪A multi-center clinical trial of 38 patients published in the New England Journal of Medicine showed a mean improvement of 25.5 letters on the ETDRS chart, with 84% of patients regaining the ability to read.

Device pricing reimbursement discussions

▪Science Corporation is preparing to launch PRIMA in Germany, where clinical trials were held, with the first commercial implant expected as early as September 2026.
▪Each PRIMA device is expected to cost in the hundreds of thousands of dollars, and Science Corporation is currently in discussions with European healthcare providers regarding reimbursement.